Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

685
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
685
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

4.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
4.4K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

86.5K
Overview
86.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same author

Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.

Blood advances·2026
Same author

Reading the "T" Leaves: Predicting Outcomes with Bispecific Antibodies in Multiple Myeloma.

Blood cancer discovery·2026
Same author

Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations.

Blood cancer discovery·2026
Same author

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.

Nature cancer·2026
Same author

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.

Clinical lymphoma, myeloma & leukemia·2025
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Related Experiment Video

Updated: Apr 4, 2026

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.7K

Immune Modulation in Hematologic Malignancies.

Madhav V Dhodapkar1, Kavita M Dhodapkar2

  • 1Departments of Internal Medicine (Hematology); Immunobiology, Yale University, New Haven, CT; Yale Cancer Center, Yale University, New Haven, CT.

Seminars in Oncology
|August 31, 2015
PubMed
Summary
This summary is machine-generated.

The immune system plays a crucial role in fighting blood cancers (hematologic malignancies). Advances in immunotherapy, including cellular therapies, offer new ways to harness immune responses against these cancers.

More Related Videos

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

14.2K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

21.6K

Related Experiment Videos

Last Updated: Apr 4, 2026

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.7K
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

14.2K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

21.6K

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • The immune system's role in hematologic malignancies is increasingly recognized, influencing tumor biology and treatment efficacy.
  • Allogeneic hematopoietic stem cell transplantation (SCT) highlights the immune system's curative potential in blood cancers.
  • The immune system contributes to the anti-tumor effects of various therapies, including immune-modulatory drugs and monoclonal antibodies.

Purpose of the Study:

  • To discuss the evolving landscape of immune modulation in hematologic malignancies.
  • To highlight unique opportunities for immunologic approaches in treating and preventing these cancers.
  • To review current and emerging immune-based therapies for blood cancers.

Main Methods:

  • Review of current literature on immunotherapy in hematologic malignancies.
  • Analysis of the distinct biological and clinical characteristics of blood cancers relevant to immune therapies.
  • Discussion of emerging therapeutic strategies, including immune-checkpoint blockade and adoptive cellular therapies.

Main Results:

  • The immune system significantly impacts the efficacy of diverse therapeutic strategies in hematologic malignancies.
  • Emerging immunotherapies like immune-checkpoint blockade and CAR T-cell therapy show significant promise.
  • Hematologic malignancies present unique challenges and opportunities for immune-based treatments compared to solid tumors.

Conclusions:

  • The field of immune-based therapy for hematologic malignancies is rapidly advancing.
  • Understanding the interplay between the immune system and blood cancers is key to developing novel treatments.
  • Hematologic malignancies offer specific advantages for the application of immunologic strategies.